Drug Trial Radar · NCT04751539
A Dose-escalation Study of AND017 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: May 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Jul 16, 2018
Primary completion
Feb 11, 2019
Study completion Feb 11, 2019
Sponsor
- Lead sponsor
- Kind Pharmaceuticals LLCIndustry
- Sponsor type
- Industry
- First posted
- Feb 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase I, randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate safety, tolerability, PKs and PDs of AND017 following oral single and multiple dose administration.
Conditions
- Healthy Volunteers
Interventions
AND017 single doseDrug
AND017 administrated as oral single-dose on Day 1 in Part A
AND017 multiple doseDrug
AND017 administrated once daily from Day 1 to Day 10 in Part B
PlaceboDrug
Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety evaluationsTime frame: 17 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Scientia Clinical Research
Randwick, New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.